OC134
Ophthalmology (unspecified)
Phase 1Active
Key Facts
About Nanomerics
Nanomerics is an award-winning, clinical-stage biotech company spun out from leading UK universities, specializing in advanced drug delivery through its proprietary Molecular Envelope Technology (MET) and METfect platforms. The company has successfully advanced its lead ophthalmology candidate, OC134, through a Phase I trial and has out-licensed a CNS-targeted analgesic, demonstrating clinical validation and partnership potential. With a focus on overcoming biological barriers for ocular, CNS, and gene therapies, Nanomerics leverages its deep academic roots and experienced leadership to repurpose and enhance known drugs, addressing significant unmet medical needs.
View full company profile